Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress

PUBT · 3d ago
Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress
  • Belite Bio flagged new Phase 3 DRAGON study results for tinlarebant in Stargardt disease; presentations are scheduled for late August 2026.
  • Management is positioning the readout as supportive of tinlarebant’s clinical profile in adolescent and adult patients, without disclosing detailed figures.
  • Investors will get the first public look at the data at the SOG congress on Aug. 27, followed by APVRS sessions on Aug. 30.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210800PRIMZONEFULLFEED9814020) on August 21, 2026, and is solely responsible for the information contained therein.